

1 **Title:**

2 **Implementation of national guidelines on antenatal magnesium sulfate for neonatal**
3 **neuroprotection in England, Scotland and Wales: Extended evaluation of the effectiveness**
4 **and cost-effectiveness of the National PReCePT Programme**

5

6 **Word count:** 3947

7

8 **Authors:**

9 Hannah B Edwards(1,2), Carlos Sillero-Rejon(1,2), Hugh McLeod(1,2), Elizabeth M Hill(1,2),
10 Brent C Opmeer(2,3), Colin Peters(4), David Odd(5,6), Frank de Vocht(1,2), Karen Luyt(7,8)

11 **Institutions:**

- 12 1. Population Health Sciences, Bristol Medical School, University of Bristol, Beacon House
13 Queens Road Bristol, BS8 1QU, UK
14 2. The National Institute for Health and Care Research Applied Research Collaboration West
15 (NIHR ARC West) at University Hospitals Bristol and Weston NHS Foundation Trust, 9th
16 Floor, Whitefriars, Lewins Mead, Bristol, BS1 2NT, UK
17 3. Vilans, National Center of Expertise for Long Term Care, P.O. Box 8228, 3503 RE, Utrecht,
18 The Netherlands
19 4. Neonatology, Royal Hospital for Children Glasgow, 1345 Govan Road, Govan, Glasgow,
20 G51 4TF, UK
21 5. Population Medicine, Cardiff University, Heath Park, Cardiff, CF14 4YS, UK.
22 6. Neonatology, Cardiff and Vale University Health Board University Hospital of Wales,
23 Heath Park, Cardiff, CF14 4XW, UK
24 7. Translational Health Sciences, Bristol Medical School, University of Bristol, Beacon House
25 Queens Road Bristol, BS8 1QU, UK
26 8. Neonatology, St Michael's Hospital, Southwell Street, Bristol, BS2 8EG, UK

27

28

29 **Corresponding author:** Hannah B Edwards Hannah.edwards@bristol.ac.uk

30 **ABSTRACT**

31 **Background:** Since 2015, UK national guidelines have recommended antenatal magnesium
32 sulfate (MgSO₄) for mothers in preterm labour (<30 weeks' gestation) to reduce the risk of
33 cerebral palsy in the preterm baby. However, implementation of this guideline in clinical
34 practice was slow, and MgSO₄ use varied between maternity units. In 2018, the PReCePT
35 programme, an evidence-based Quality Improvement intervention to improve use of
36 MgSO₄, was rolled-out across England. Earlier evaluation found this programme to be
37 effective and cost-effective over the first 12 months. We extended the original evaluation to
38 determine the programme's longer-term impact over four years, its impact in later preterm
39 births, impact of the COVID-19 pandemic, and to compare MgSO₄ use in England, Scotland,
40 and Wales.

41 **Methods:** Quasi-experimental longitudinal study using data from the National Neonatal
42 Research Database on babies born <30 weeks' gestation and admitted to an NHS neonatal
43 unit. Primary outcome was the proportion of eligible mothers receiving MgSO₄, aggregated
44 to the national level. Impact of PReCePT on MgSO₄ use was estimated using multivariable
45 linear regression. The net monetary benefit (NMB) of the programme was estimated.

46 **Results:** MgSO₄ administration rose from 65.8% in 2017 to 85.5% in 2022 in England.
47 PReCePT was associated with 5.8 percentage points improvement in uptake (95%CI 2.69 to
48 8.86, p<0.001). Improvement was greater when including older preterm births (<34 weeks'
49 gestation, 8.67 percentage points, 95%CI 6.38 to 10.96, p<0.001). Most gains occurred in the
50 first two years following implementation. PReCePT had a NMB of £597,000 with 89%
51 probability of being cost-effective. Following implementation, English uptake appeared to

52 accelerate compared to Scotland and Wales. There was some decline in use coinciding with
53 the onset of the pandemic.

54 **Conclusions:** The PReCePT Quality Improvement programme cost-effectively improved use
55 of antenatal MgSO₄, with benefits to the babies who have been protected from cerebral
56 palsy.

57

58 **What is already known on this topic**

- 59 • Antenatal magnesium sulphate (MgSO₄) reduces the risk of cerebral palsy in babies born
60 preterm.
- 61 • The National PReCePT Quality Improvement Programme (NPP) effectively and cost-
62 effectively improved use of MgSO₄ in England in the first 12 months of implementation,
63 but sustaining quality improvements over time is often challenging.

64 **What this study adds**

- 65 • Using a quasi-experimental design and routinely collected, longitudinal, patient-level
66 data, this study found that the NPP had sustained effectiveness and cost-effectiveness
67 over four years following implementation.
- 68 • Improvement may have been accelerated in England, compared to Scotland and Wales,
69 where the NPP was not formally implemented.

70 **How this study might affect research, practice or policy**

- 71 • This study demonstrates that dedicated national programmes can cost-effectively
- 72 achieve improvements in perinatal care. The PReCePT model could be used as an
- 73 implementation blueprint for other quality improvement initiatives in perinatal care.

74 INTRODUCTION

75 Since 2015 the World Health Organisation (WHO)(1) and the UK National Institute for Health
76 and Care Excellence (NICE)(2) have recommended administration of magnesium sulfate
77 (MgSO_4) in preterm deliveries <30 weeks' gestation as a core part of maternity care. This
78 follows strong evidence that when given antenatally to women in preterm labour, MgSO_4
79 reduces the risk of cerebral palsy (CP) in preterm babies by around 30%(3). Historically, use
80 of this treatment has been inconsistent, with only 64% of eligible women in England being
81 treated in 2017. High regional variation in uptake also indicates inequalities in perinatal
82 care(4).

83 As well as the significant impact of CP on affected individuals and their families(5), there are
84 lifetime societal costs of approximately £1m per affected individual(6), and £1.8 billion
85 annually on NHS clinical negligence litigation (half of the total NHS litigation expenditure)(7).
86 Incidence of CP has been estimated at around 1.5 per 1000 livebirths in the UK(8), with
87 preterm birth as the leading risk factor(9-11). This highlights the importance of funding
88 effective, and cost-effective, strategies to reduce the risk of CP associated with preterm
89 birth. It is estimated that one case of CP can be prevented, below 30 weeks' gestation, for
90 every 37 mothers treated with MgSO_4 , and around 200 cases of CP per year could be
91 avoided by consistent administration of MgSO_4 during labour(3).

92 In 2018, NHS England rolled-out the National PReCePT (Prevention of cerebral palsy in
93 preterm labour) Programme (NPP). This was a quality improvement (QI) programme for
94 maternity units, providing clinical guidance, training, learning resources, midwife backfill
95 funding, and QI support, to improve maternity staff awareness, and increase use of MgSO_4

96 for mothers in preterm labour. The aim was to reach $\geq 85\%$ uptake in eligible mothers across
97 all maternity units in England. The programme was delivered by regional Academic Health
98 Science Networks (AHSNs, now Health Innovation Networks). Evaluation of the first 12
99 months of the programme found it to be effective, improving MgSO_4 use by an estimated
100 6.3 percentage points, with an estimated net monetary benefit of £866 per preterm baby,
101 and $>95\%$ probability of being cost-effective(12). However it is unknown whether these
102 improvements were sustained over time, and sustainability in large scale implementation
103 programmes is often a problem (and measurement of sustained effect often neglected)(13).

104 The primary aim of this study, therefore, was to evaluate the NPP's longer-term, sustained
105 effectiveness and cost-effectiveness over the first four years following implementation. A
106 key secondary aim was to explore the impact of the NPP on all babies born up to 34 weeks'
107 gestation; NICE guidelines recommend treatment for births up to 30 weeks', and
108 'consideration of treatment' for older preterm births up to 34 weeks'. Other secondary aims
109 were to explore the impact of the COVID-19 pandemic on MgSO_4 use, and to compare
110 MgSO_4 use in England with that in the devolved nations Scotland and Wales. This evaluation
111 is part of a larger programme of work, including qualitative interviews to explore how the
112 devolved nations were responding to the NICE guidance, reported elsewhere(14).

113 **METHODS**

114 **Design**

115 This was a quasi-experimental study for the evaluation of the NPP's effectiveness and cost-
116 effectiveness. The pre-registered Statistical Analysis Plan and Health Economic Analysis Plan
117 were uploaded to the Open Science Framework prior to analyses: <https://osf.io/be76s/>.

118 **Intervention**

119 The intervention being implemented was the National PReCePT Programme (NPP), as
120 described above and fully detailed elsewhere(12), for the adoption of MgSO₄ as a
121 neuroprotectant in preterm births.

122 **Setting**

123 NHS maternity units in England, Scotland and Wales. Within maternity units, analysis was
124 performed on aggregated data on babies born preterm <30 weeks' gestation, and admitted
125 to an NHS neonatal unit, between January 2014 to December 2022. All maternity units in
126 England, Scotland and Wales were included, excepting the five units in England that took
127 part in the original PReCePT pilot study(15) and were therefore not part of the NPP.

128 **Data sources**

129 Data on eligible babies and their mothers were obtained from the National Neonatal
130 Research Database (NNRD), which holds individual-level, pseudonymised, routinely
131 collected patient data on babies admitted to an NHS neonatal unit. Costs associated with
132 the NPP were estimated in the original evaluation(12).

133 **Effectiveness evaluation**

134 *Outcome*

135 The main implementation outcome was MgSO₄ uptake over time. MgSO₄ uptake was
136 defined as the proportion of eligible mothers recorded as receiving MgSO₄ at a maternity
137 unit, expressed as a percentage. For consistency with nationally reported data, mothers
138 with missing MgSO₄ data were excluded from this calculation. This was computed per

139 month per unit, and reported as a percentage. For consistency with nationally reported data
140 only data on singletons and the first born (i.e. one infant) from each multiple birth were
141 included in the calculation.

142 *Descriptive analysis*

143 Maternity unit, population characteristics, and MgSO₄ use were descriptively reported by
144 nation and time-period.

145 *Primary analysis*

146 Primary analysis was an interrupted time series using English data aggregated to the
147 national level (mean national MgSO₄ uptake per month, across all English maternity units). A
148 multivariable linear regression model was used to estimate the difference in mean MgSO₄
149 uptake from before (the 1-year period before) to after (the four-years follow-up)
150 implementation of the NPP in England. The model adjusted for an underlying linear time
151 trend, and mother and baby characteristics aggregated nationally per month (mean
152 maternal age, Index of Multiple Deprivation (IMD) decile(16), baby's birthweight adjusted
153 for gestational age as a z-score, and proportion reported smokers, white British ethnicity,
154 type of birth (c-section versus vaginal delivery), and multiple births. The model was further
155 adjusted for a non-linear temporal component to account for the ceiling effect and
156 reduction in rate of change at levels close to the ceiling. Data on paternal age and ethnicity
157 were explored as potential confounding factors, but were excluded due to high levels of
158 missing data, and expected collinearity with other variables (maternal and paternal age
159 tends to correlate, as does maternal and paternal ethnicity). Potential interaction was
160 explored between mean MgSO₄ uptake and level of maternity unit (Neonatal Intensive Care

161 Unit (NICU), the highest-level unit versus Special Care Baby Unit (SCBU) or Local Neonatal
162 Unit (LNU), lower level units)). This was because it was anticipated that performance might
163 differ by type of unit: data from the original study indicated that smaller units tended to
164 have lower starting uptake levels, so more room for improvement compared to larger
165 NICUs.

166 *Sensitivity and subgroup analyses*

167 As sensitivity analyses the above model was run on data aggregated to (a) the maternity-
168 unit-level rather than the national level, and (b) the individual rather than national level.
169 These two models additionally adjusted for type of maternity unit (NICU vs SCBU/LNU),
170 regional clustering by AHSN, and were weighted on the number of eligible births per unit
171 per month. Other sensitivity analyses included assessing (c) the impact of excluding a ‘fuzzy’
172 implementation start window of +/-2 months, to account for some units starting slightly
173 earlier or later than their officially recorded start date; (d) the impact of excluding the final 2
174 months of data, due to concerns about completeness of the most recent data for some
175 units; (e) the impact of using a longer pre-NPP comparison period of four years; and (f) the
176 impact of including more mature pre-term babies up to 34 weeks’ gestation in the analysis.
177 A sub-group analysis was performed on the 40 units that had participated in a connected
178 study, an RCT nested within the main NPP(17), as their performance could plausibly differ
179 from other maternity units.

180 **Economic evaluation**

181 *MgSO₄ treatment cost-effectiveness*

182 Economic analysis combines evidence of the treatment (MgSO_4) effect with evidence of the
183 implementation (NPP) effect(18). For the former, estimates of the cost-effectiveness of
184 MgSO_4 treatment were adopted from Bickford and colleagues' results(6, 19, 20), with their
185 estimates converted to GBP currency and 2019 prices (Supplementary Table 1). This analysis
186 accounts for the health impacts and cost savings of MgSO_4 administered in births <30 and
187 <32 weeks' gestation.

188 *NPP implementation costs and effectiveness*

189 The mean implementation cost per unit of the NPP was estimated from data supplied by the
190 NPP team and PReCePT study team, and reported previously(12, 17). The total cost of the
191 NPP at a national level was estimated at £936,747(12) (which includes the funded backfill of
192 clinical time for NPP 'champion' midwives at each maternity unit, and regional support from
193 AHSNs).

194 From the multivariable linear regression model described above, we estimated the NPP
195 effectiveness as the difference between the predicted level of MgSO_4 use over time
196 compared to a counterfactual level of MgSO_4 use, representing what may have occurred in
197 the absence of the NPP, assuming a continuation of the pre-NPP trend in MgSO_4 uptake. The
198 main measure of NPP effectiveness was the area-between-the-curves. Primary analysis used
199 a linear distribution to estimate the counterfactual based on the pre-NPP predicted trend.
200 Sensitivity analysis used a beta distribution to estimate this counterfactual, to account for
201 MgSO_4 uptake as a proportion.

202 *Policy cost-effectiveness analysis*

203 The cost-effectiveness analysis was conducted from a societal lifetime perspective. Net
204 monetary benefit (NMB) of the NPP was estimated over the four years since its launch, by
205 combining analysis of the costs and effectiveness of the NPP with the lifetime societal cost,
206 and health gains associated with MgSO₄ treatment. This analysis used a framework
207 previously developed to conduct economic evaluations of implementation initiatives(21). A
208 willingness-to-pay threshold of £20,000 per Quality Adjusted Life Year (QALY) gained was
209 used to determine NPP cost-effectiveness, following NICE guidelines(22). A positive NMB
210 indicated that the implementation initiative was cost-effective. The net increment of the
211 number of patients that received MgSO₄, and the implementation cost-effectiveness per
212 additional patient treated, was also estimated. The analysis used the area-between-the-
213 curves estimate of NPP effectiveness with a linear counterfactual, and a sensitivity analysis
214 using a beta counterfactual.

215 Probabilistic analysis was conducted using a Monte Carlo simulation with 10,000 samples
216 drawn from parameter distributions. Point estimates, probabilistic distribution assumptions,
217 and parameter source estimates are reported in Supplementary Table 2. Cost-effectiveness
218 planes and cost-effectiveness acceptability curves were plotted for willingness-to-pay
219 thresholds from zero to £100,000 per QALY gained for the policy cost-effectiveness of the
220 NPP intervention.

221 *Secondary economic analysis*

222 As evidence on the lifetime cost-effectiveness of antenatal MgSO₄ covers babies born up to
223 32 weeks' gestation, cost-effectiveness analysis was performed only for babies <30 and <32
224 weeks' gestation.

225 Statistical software Stata version 17 and R version 4.3.1 were used for all statistical analyses.

226 **RESULTS**

227 **Baseline characteristics**

228 In 2017, the year before NPP roll-out, a total of 4091 babies born under 30 weeks'
229 gestational age were admitted to neonatal units in England, 296 in Scotland, and 182 in
230 Wales. The majority of births were in maternity units with a NICU (62.6% in England, 83.5%
231 in Scotland, 63.0% in Wales). Other than the number of babies admitted, study populations
232 were largely comparable across the three nations with respect to other covariates (Table 1).

233 **Historical trends**

234 In 2014, MgSO₄ uptake was around 20% in England, 40% in Scotland, and 10% in Wales.
235 Uptake improved over time in all three nations, with the rate of change slowing down at
236 higher levels of treatment (ceiling effect). Although national levels appeared to converge in
237 the latest 2022 data, there was visual suggestion that since the launch of the NPP, uptake
238 may have been accelerated in England compared to the devolved nations. However, due to
239 relatively smaller numbers, there was high variation in monthly uptake for Scotland and
240 Wales, which limited formal assessment of parallel trends (Figure 1).

241 **Pre/post-NPP comparison**

242 In England, overall MgSO₄ uptake rose from 65.8% in 2017 to 85.5% in 2022 (62.3% to 81.4%
243 in Scotland, 61.6% to 86.6% in Wales). The amount of missing data fell from around 5% in
244 2017 to under 1% in 2022. Imminent delivery was the most commonly recorded reason for
245 not giving MgSO₄, accounting for around 15% of eligible babies in 2017, dropping to around

246 10% in England and Wales in 2022. The number recorded as not offered MgSO₄ fell from
247 around 7% to around 1% across all three nations (Supplementary Table 3).

248 **Estimate of NPP effectiveness**

249 The adjusted model estimated an average 5.8 (95% CI 2.7 to 8.9, p<0.001) percentage point
250 increase in MgSO₄ uptake in England across the four years post-NPP, compared to the one
251 year pre-NPP. Much of the gains appeared to take place as a step-change in the first two
252 years of the programme. There were additional gains in years three and four (at which point
253 the improvement became statistically significant), although confidence intervals overlap
254 with estimates from the first two years (Table 2).

255 Estimates were robust to sensitivity analyses (Table 2). There was indication of greater
256 improvement in MgSO₄ use when including babies up to 34 weeks' gestational age in the
257 analysis (8.7 percentage point increase in MgSO₄ uptake, 95%CI 6.4 to 11.0, p<0.001), and in
258 the 40 units in the PReCePT RCT (8.6 percentage point increase in MgSO₄ uptake, 95%CI 2.4
259 to 14.9, p=0.007). There was some evidence that lower-level maternity units improved more
260 than higher-level units (SCBUs and LNU: 9.1 percentage points change, 95%CI 3.9 to 14.3,
261 p=0.001. NICUs: 4.1 percentage points change, 95%CI 0.6 to 7.6, p=0.022), reflecting the fact
262 that NICUs tended to have higher starting levels.

263 **Impact of the COVID-19 pandemic**

264 In 2020 there was a slight declining trend in MgSO₄ use coinciding with the start of the
265 COVID-19 pandemic, which continued to the end of the dataset at the end of 2022. The use
266 of antenatal steroids (another, more well-established protective treatment for preterm
267 babies) had an almost identical decline over this same period (Supplementary Figure 1).

268 **Economic evaluation**

269 The impact of the NPP is illustrated in Figure 2, using a linear distribution (Figure 2a) and a
270 beta distribution (Figure 2b) as counterfactuals. Probabilistic analysis estimated that the
271 additional use of MgSO₄ attributed to the NPP was equivalent to 3.0 percentage point
272 improvement on average over seven months, which equates to an additional 64 of the 2136
273 pre-term (<30 weeks' gestation) babies receiving treatment (Table 3). The lifetime and
274 societal NMB of the NPP was about £597000, or £279 per preterm baby. The probability of
275 the NPP being cost-effective was 89% (Table 3, Supplementary Figure 2).

276 The sensitivity analysis with the beta distribution counterfactual, estimated a longer period
277 of impact (an additional three months) over which there was additional use of MgSO₄
278 attributed to the NPP equivalent to a 2.9 percentage point improvement on average over 10
279 months, which equates to an additional 92 of 3129 pre-term babies receiving treatment
280 (Figure 2b). Accounting for the total cost of the NPP, and the lifetime health gains and cost
281 savings of MgSO₄ treatment, the NMB was estimated to be £1.3m, or £400 per preterm
282 baby. The probability of the NPP being cost-effective in this analysis was 100% (Table 3).

283 Expanding the analysis to include babies up to 32 weeks' gestation estimated additional use
284 of MgSO₄ attributed to the NPP equivalent to a 4.4 percentage point improvement on
285 average over nine months, which equates to an additional 215 pre-term babies treated. As
286 the total cost of the NPP was fixed, and not sensitive to the number of babies treated, the
287 NMB of the NPP was about £4.2m, or £853 per pre-term baby. The probability of NPP being
288 cost-effective was 100% at the willingness-to-pay threshold of £20,000 per QALY gained
289 (Supplementary Table 4 and Supplementary Figure 3). For the sensitivity analysis with the

290 beta distribution the NMB of NPP was about £5.4m, or £700 per preterm baby. The
291 probability of cost-effectiveness was 100% (Supplementary Table 4).

292 Expanding the analysis further again to include babies up to 34 weeks' gestation shows that
293 the additional use of MgSO₄ attributed to the NPP was equivalent to 7.3 percentage point
294 improvement on average over seven months. This means an additional 961 babies receiving
295 treatment. Using a beta distribution for the counterfactual showed a 6.5 percentage point
296 improvement attributed to the NPP over 12 months (698 additional patients). The NMB of
297 the NPP was not calculated for this more mature group of preterm babies, as currently there
298 is no available estimate for the cost-effectiveness of MgSO₄ treatment for babies born
299 above 31⁺⁶ weeks' gestation.

300 **DISCUSSION**

301 The original NPP evaluation found evidence of improved MgSO₄ use over the first 12 months
302 following implementation. This extended evaluation found that the improvements have
303 largely been sustained over the first four years following implementation, although there
304 was suggestion of a slight decline in use coinciding with the pandemic. The benefits applied
305 both to the target population of births <30 weeks' gestation, but also to more mature
306 preterm babies up to 34 weeks' gestation. The programme was associated with a net
307 monetary benefit of about £0.6m for babies up to 29 weeks' gestation, rising to about
308 £4.2m when babies up to 31 weeks' gestation are included. Compared to the devolved
309 nations, uptake appeared to improve faster in England in the first two years following the
310 NPP launch. By the end of 2022 however, the three nations were broadly comparable with
311 delivery of MgSO₄ to around 81-87% of eligible mothers. This is at the higher end of levels

312 reported internationally (69% to 87%(23-26)) following guidelines or interventions to
313 increase MgSO₄ uptake.

314 Comparisons between England, Scotland, and Wales should be interpreted with caution:
315 firstly because there is high variability due to small numbers in the devolved nations data,
316 which limits formal statistical comparison of trends. Secondly because Scotland and Wales
317 were implementing their own MgSO₄ initiatives (e.g. MCQIC(27), PERIPrem Cymru(28)),
318 complicating their position as a control group. Thirdly because there was also accessing of
319 the English PReCePT toolkit and implementation resources during this time period (66
320 downloads from Wales, 32 from Scotland, 2018-2022, AHSN data, unpublished). This
321 'contamination' means that the boundaries of the target population are fuzzy, and again the
322 devolved nations cannot be considered optimal controls. Finally, the three nations' trends in
323 uptake prior to the NPP were also not parallel, due to variation in starting levels in 2014,
324 and this meant that formal statistical comparison of their improvements (for example
325 including all three nations in an interrupted time series or difference in difference analysis)
326 was not appropriate.

327 The COVID-19 pandemic could plausibly have impacted on MgSO₄ use: the broad impact on
328 staffing and quality of care affecting all parts of the NHS(29), and a specific impact on
329 expecting mothers who may have presented at hospital later due to concerns about
330 infection and giving birth alone, could both lead to missed opportunities to give MgSO₄(30,
331 31). Analysis of future data will be important to explore what may be a temporary negative
332 effect of the pandemic, versus what might be a natural waning of the initially positive
333 effects of the NPP. From the observation that antenatal steroid use (historically well-
334 established at high levels) declined almost identically to MgSO₄ use over the pandemic

335 period, the national decline may be associated with the pandemic. This finding is concerning
336 and may illustrate the fragility of complex healthcare systems. Further follow up is
337 important to monitor both metrics.

338 The observation of greater improvements in uptake when including more mature preterm
339 births (all babies born up to 34 weeks' gestation) is interesting. While the more mature
340 preterm infants represent a much larger proportion of preterm births, interpretation is
341 complex; their profile of underpinning antenatal disease, and hence their presentation to
342 healthcare, may vary from the more extreme preterm presentation. This could be expected
343 to impact on the subsequent ease of delivering antenatal MgSO₄. Evidence on the protective
344 effect of MgSO₄ in babies 30-34 weeks' is less clear(3, 32, 33) and although long term
345 neurological impacts remain higher in these groups than term-born peers(34), due to their
346 greater numbers, even small shifts in risks may have substantial population benefits(35).

347 It is likely to be more difficult to improve from 85% to 90% uptake, compared to improving
348 from 65% to 70% uptake. Further overall increases in MgSO₄ use may be a challenge without
349 concerted effort at the lower-performing units. However, as some units do report higher
350 (>90%) uptake (perhaps through better triaging and monitoring of symptoms), we argue
351 that their performance should be used as the benchmark for quality of care, and investment
352 in supporting the lower-performing units is likely to be cost-effective.

353 The creation of clinical guidelines alone is often not enough to ensure that evidence-based
354 interventions become standard practice. A relevant example here is the case of antenatal
355 steroids, which in the absence of a programme dedicated to getting this evidence into
356 practice, took several decades for their use to become standard care. In contrast, and in the

357 context of the NPP, the same improvements in use of MgSO₄ were achieved within a few
358 years.

359 **Strengths and limitations**

360 This evaluation included effectiveness and cost-effectiveness analysis to capture the impact
361 of the NPP implementation. These types of analysis have been highlighted as key
362 components of implementation science research(18, 36). Results from the main and
363 sensitivity analyses were consistent. Data covered a period of eight years, giving adequate
364 time for analysis of trends. The study benefitted from high quality, routinely collected,
365 national, longitudinal patient-level data. The key advantages of this comprehensive real-
366 world data is that it provides high generalisability (included all maternity units in England,
367 Scotland, and Wales, reflecting the nationwide situation), shows effectiveness in real-world
368 conditions, and is less vulnerable to some biases such as recall, observer, and attrition bias.
369 A limitation is that this sort of data does not necessarily include all the covariates of interest,
370 and data quality and completeness is not always consistent across all sites.

371 A key limitation is that residual confounding cannot be excluded. We have tried to minimise
372 the impact of confounding through robust analytic methods, and interpret findings with
373 caution. In addition to the PReCePT programme, there are other factors that likely will have
374 impacted on uptake, including the publication of definitive evidence on the protective
375 effective of MgSO₄ in 2009(37) MgSO₄ use being reliably recorded as a Neonatal Data
376 Analysis Unit (NDAU) audit quality metric for maternity units in 2014-15, and its use
377 becoming a formal recommendation in the NICE Guidance in 2015(2). Other factors related
378 to PReCePT include the original pilot study publishing positive results in 2017; and
379 discussions with unit leads about the proposed NPP in 2017. The National Neonatal Audit

380 Programme (NNAP) concluded in their report on 2020 data that “This rapid improvement [in
381 MgSO₄ use], particularly seen in England, is likely to result from the targeted approach of
382 the PReCePT quality improvement initiative.”(38)

383 Another limitation is that the population investigated here included liveborn babies
384 admitted to a neonatal unit, rather than the total population of mothers eligible for MgSO₄.
385 The rate of MgSO₄ uptake may be different between these two populations, although any
386 health benefit would only be realised in those investigated in this work. It would be an
387 advantage if future research could explore, and compare, uptake in both populations, and
388 the survival and neurodevelopmental outcomes for those preterm babies who did, and did
389 not, receive MgSO₄.

390 The Health Foundation and Health Data Research UK recently listed PReCePT as a case study
391 model for a Learning Health System (i.e. a systematic approach to iterative, data-driven
392 quality improvement(39)) and we propose that the PReCePT model could be used as an
393 implementation blueprint for other quality improvement initiatives.

394 **CONCLUSIONS**

395 Implementation of the National PReCePT Programme has plausibly helped accelerate
396 uptake of MgSO₄ in England, improving maternal and neonatal care, and positively
397 impacting society in terms of direct patient benefit and future cost savings. Failure to deliver
398 MgSO₄ to eligible mothers should be considered inadequate care, and not financially
399 sustainable for the NHS. MgSO₄ as a quality metric should continue to be closely monitored,
400 and further intervention may be warranted to achieve optimal treatment levels. Future

401 research should quantify the patient outcomes in this same population, specifically the
402 cases of cerebral palsy prevented, associated with the improvements in use of MgSO₄.

403 Abbreviations

CP	Cerebral Palsy
MgSO ₄	Magnesium Sulphate
NDAU	Neonatal Data Analysis Unit
NMB	Net Monetary Benefit
NNRD	National Neonatal Research Database
NPP	National PReCePT Programme
PReCePT	Prevention of Cerebral Palsy in PreTerm Labour
QI	Quality Improvement

404

405 REFERENCES

- 406 1. Organization) WWH. WHO recommendations on interventions to improve preterm birth
407 outcomes. Switzerland; 2015. Contract No.: ISBN: 978 92 4 150898 8.
- 408 2. (NICE) NifHaCE. Preterm labour and birth (NG25). 2015.
- 409 3. Crowther CA, Middleton PF, Voysey M, Askie L, Duley L, Pryde PG, et al. Assessing the
410 neuroprotective benefits for babies of antenatal magnesium sulphate: An individual participant data
411 meta-analysis. PLOS Medicine. 2017;14(10):e1002398.
- 412 4. (NNAP) NNAP. Annual report 2018. UK: RCPH; 2018.
- 413 5. Odding E, Roebroek ME, Stam HJ. The epidemiology of cerebral palsy: Incidence,
414 impairments and risk factors. Disability and Rehabilitation. 2006;28(4):183-91.
- 415 6. Bickford CD ML, Mitton C, Kruse M, Synnes AR, Sawchuck D, et al. Magnesium sulphate for
416 fetal neuroprotection: a cost-effectiveness analysis. BMC Health Services Research. 2013;13(1):527.
- 417 7. Resolution N. NHS Resolution Annual report and accounts 2019/2020 London; 2020 July
418 2020. Contract No.: HC 499.
- 419 8. Kobezda T, Rehm A. Live births with cerebral palsy at a tertiary maternity hospital: incidence
420 and associated risk factors over a 17-year period. Journal of obstetrics and gynaecology : the journal
421 of the Institute of Obstetrics and Gynaecology. 2022;42(7):2771-8.
- 422 9. O'Shea TM, Allred EN, Dammann O, Hirtz D, Kuban KCK, Paneth N, et al. The ELGAN study of
423 the brain and related disorders in extremely low gestational age newborns. Early Human
424 Development. 2009;85(11):719-25.
- 425 10. Vincer MJ, Allen AC, Joseph KS, Stinson DA, Scott H, Wood E. Increasing prevalence of
426 cerebral palsy among very preterm infants: a population-based study. Pediatrics. 2006;118(6):e1621-
427 6.

- 428 11. Himpens E, Van den Broeck C, Oostra A, Calders P, Vanhaesebrouck P. Prevalence, type,
429 distribution, and severity of cerebral palsy in relation to gestational age: a meta-analytic review.
430 *Developmental Medicine & Child Neurology*. 2008;50(5):334-40.
- 431 12. Edwards HB, Redaniel MT, Sillero-Rejon C, Margelyte R, Peters TJ, Tilling K, et al. National
432 PRiCePT Programme: a before-and-after evaluation of the implementation of a national quality
433 improvement programme to increase the uptake of magnesium sulfate in preterm deliveries.
434 *Archives of Disease in Childhood - Fetal and Neonatal Edition*. 2023;108(4):342-7.
- 435 13. Proctor E, Luke D, Calhoun A, McMillen C, Brownson R, McCrary S, et al. Sustainability of
436 evidence-based healthcare: research agenda, methodological advances, and infrastructure support.
437 *Implement Sci*. 2015;10:88.
- 438 14. Edwards HB SRC, Pithara-McKeown C, De Vocht F, McLeod H, Redwood S, Hill L, Opmeer B,
439 Odd D, Luyt K. PRiCePT Devolved Nations: Evaluation Report University of Bristol; 2024 5th February
440 2024.
- 441 15. Burhouse A, Lea C, Ray S, Bailey H, Davies R, Harding H, et al. Preventing cerebral palsy in
442 preterm labour: a multiorganisational quality improvement approach to the adoption and spread of
443 magnesium sulphate for neuroprotection. *BMJ Open Quality*. 2017;6(2).
- 444 16. GOV.UK. National statistics: English indices of deprivation 2019. In: Ministry of Housing CLG,
445 editor. 2019.
- 446 17. Edwards HB, Redaniel MT, Sillero-Rejon C, Pithara-McKeown C, Margelyte R, Stone T, et al.
447 Quality improvement interventions to increase the uptake of magnesium sulphate in preterm
448 deliveries for the prevention of cerebral palsy (PRiCePT study): a cluster randomised controlled trial.
449 *BJOG: An International Journal of Obstetrics & Gynaecology*. 2023;n/a(n/a).
- 450 18. Proctor E, Silmere H, Raghavan R, Hovmand P, Aarons G, Bunger A, et al. Outcomes for
451 implementation research: conceptual distinctions, measurement challenges, and research agenda.
452 *Adm Policy Ment Health*. 2011;38(2):65-76.
- 453 19. Shih STF, Tonmukayakul U, Imms C, Reddihough D, Graham HK, Cox L, et al. Economic
454 evaluation and cost of interventions for cerebral palsy: a systematic review. *Developmental
455 medicine and child neurology*. 2018;60(6):543-58.
- 456 20. Cahill AG, Odibo AO, Stout MJ, Grobman WA, Macones GA, Caughey AB. Magnesium sulfate
457 therapy for the prevention of cerebral palsy in preterm infants: a decision-analytic and economic
458 analysis. *American Journal of Obstetrics & Gynecology*. 2011;205(6):542.e1-.e7.
- 459 21. Sillero-Rejon C HW, McLeod H, Opmeer B, Luyt K. Economic evaluation in implementation
460 science: A reconciled approach evaluating programmes to increase the uptake of magnesium
461 sulphate in pre-term births. Pre-print ed. ResearchSquare:
462 <https://www.researchsquare.com/article/rs-2678140/v2>; 2023.
- 463 22. NICE. Developing NICE guidelines: the manual (PMG20). London: NICE; 2014.
- 464 23. Ow LL, Kennedy A, McCarthy EA, Walker SP. Feasibility of implementing magnesium sulphate
465 for neuroprotection in a tertiary obstetric unit. *Australian and New Zealand Journal of Obstetrics and
466 Gynaecology*. 2012;52(4):356-60.
- 467 24. Keir AK, Shepherd E, McIntyre S, Rumbold A, Groves C, Crowther C, et al. Antenatal
468 magnesium sulfate to prevent cerebral palsy. *Archives of disease in childhood Fetal and neonatal
469 edition*. 2022;107(2):225-7.
- 470 25. Chollat C, Bertrand E, Petit-Ledo A, de Vansay C, Voisin C, Dabaj I, et al. Cerebral Palsy in
471 Very Preterm Infants: A Nine-Year Prospective Study in a French Population-Based Tertiary Center.
472 *The Journal of Pediatrics*. 2021;237:183-9.e6.
- 473 26. Doyle LW, Spittle AJ, Olsen JE, Kwong A, Boland RA, Lee KJ, et al. Translating antenatal
474 magnesium sulphate neuroprotection for infants born <28 weeks' gestation into practice: A
475 geographical cohort study. *Aust N Z J Obstet Gynaecol*. 2021;61(4):513-8.
- 476 27. Scottish Patient Safety Programme (SPSP) Maternity and Children Quality Improvement
477 Collaborative (MCQIC). In: Scotland HI, editor.: NHS Scotland; 2023.
- 478 28. PERIPrem Cymru for professionals. NHS Wales; 2023.

- 479 29. Jones H, Seaborne M, Cowley L, Odd D, Paranjothy S, Akbari A, et al. Population birth
480 outcomes in 2020 and experiences of expectant mothers during the COVID-19 pandemic: A 'born in
481 Wales' mixed methods study using routine data. *PLoS One*. 2022;17(5):e0267176.
- 482 30. Dasgupta T, Horgan G, Peterson L, Mistry HD, Balls E, Wilson M, et al. Women's experiences
483 of maternity care in the United Kingdom during the COVID-19 pandemic: A follow-up systematic
484 review and qualitative evidence synthesis. *Women and Birth*. 2024;37(3):101588.
- 485 31. Aydin E, Glasgow KA, Weiss SM, Khan Z, Austin T, Johnson MH, et al. Giving birth in a
486 pandemic: women's birth experiences in England during COVID-19. *BMC Pregnancy Childbirth*.
487 2022;22(1):304.
- 488 32. Crowther CA, Ashwood P, Middleton PF, McPhee A, Tran T, Harding JE, et al. Prenatal
489 Intravenous Magnesium at 30-34 Weeks' Gestation and Neurodevelopmental Outcomes in
490 Offspring: The MAGENTA Randomized Clinical Trial. *JAMA*. 2023;330(7):603-14.
- 491 33. Louis JM, Randis TM. Intrapartum Magnesium for Neuroprotection: Revisiting Gestational
492 Age Criteria. *JAMA*. 2023;330(7):597-8.
- 493 34. Odd D, Evans D, Emond A. Preterm Birth, Age at School Entry and Long Term Educational
494 Achievement. *PLOS ONE*. 2016;11(5):e0155157.
- 495 35. Odd D, Evans D, Emond AM. Prediction of school outcome after preterm birth: a cohort
496 study. *Archives of disease in childhood*. 2019;104(4):348-53.
- 497 36. Hull L, Goulding L, Khadjesari Z, Davis R, Healey A, Bakolis I, et al. Designing high-quality
498 implementation research: development, application, feasibility and preliminary evaluation of the
499 implementation science research development (ImpRes) tool and guide. *Implementation Science*.
500 2019;14(1):80.
- 501 37. Doyle LW, Crowther CA, Middleton P, Marret S, Rouse D. Magnesium sulphate for women at
502 risk of preterm birth for neuroprotection of the fetus. *The Cochrane database of systematic reviews*.
503 2009(1):Cd004661.
- 504 38. (NNAP) NNAP. Annual report 2020. UK: RCPH; 2020.
- 505 39. Hardie T HT, Thornton-Lee N, Home J, Pereira P. Developing learning health systems in the
506 UK: Priorities for action. 2022 September 2022.

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523 **Table 1: Baby, mother, and maternity unit characteristics by nation at baseline⁰**

	England	Scotland	Wales
Socio-demographic characteristics of babies			
Number of babies (N) ¹	4091	296	182
Gestational age (median weeks, IQR)	27.7 (26.0,28.9)	27.9 (26.6,28.9)	28.0 (26.6,28.9)
22 weeks	14 (0.3%)	0 (0.0%)	3 (1.7%)
23 weeks	225 (5.5%)	12 (4.1%)	6 (3.3%)
24 weeks	374 (9.1%)	24 (8.5%)	9 (5.0%)
25 weeks	407 (10.0%)	19 (6.4%)	12 (6.6%)
26 weeks	530 (13.0%)	34 (11.5%)	22 (12.1%)
27 weeks	644 (15.7%)	58 (19.6%)	34 (18.7%)
28 weeks	886 (21.7%)	74 (25.0%)	56 (30.8%)
29 weeks	1011 (24.7%)	74 (25.0%)	40 (22.0%)
Birthweight (median grams, IQR)	961 (760,1180)	1010 (780,1218)	1030 (782,1240)
Male sex (N, %)	2271 (55.5%)	156 (52.7%)	102 (56.0%)
Multiple births (N, %)	1004 (24.5%)	78 (26.4%)	40 (22.0%)
Socio-demographic characteristics of parents			
Number of mothers (N) ²	3573	254	162
Maternal age (years, mean, SD)	30.5 (6.1)	29.5 (5.9)	28.7 (6.0)
Mothers reporting white British ethnicity (N, %)	1793 (50.2%)	155 (61.0%)	116 (71.6%)
Non-white British	1186 (33.2%)	34 (13.4%)	15 (9.3%)
Missing data	594 (16.6%)	65 (25.6%)	31 (19.1%)
Level of deprivation (IMD quintile, N, %) ³			
(Most deprived) 1	1215 (34.0%)	88 (34.7%)	51 (31.5%)
2	804 (22.5%)	60 (23.6%)	30 (18.5%)
3	611 (17.1%)	33 (13.0%)	37 (22.8%)
4	487 (13.6%)	36 (14.2%)	20 (12.4%)
(Least deprived) 5	391 (10.9%)	28 (11.0%)	21 (13.0%)
Missing data	65 (1.8%)	9 (3.5%)	3 (1.9%)
Any reported smoking history (N, %)	602 (16.9%)	38 (15.0%)	43 (26.5%)
Clinical characteristics of mothers			
Hypertension in pregnancy (N, %)	163 (4.6%)	16 (6.3%)	5 (3.1%)
Premature rupture of membranes (N, %)	603 (16.9%)	49 (19.3%)	30 (18.5%)
Caesarean section (N, %)	1888 (52.8%)	152 (59.8%)	87 (53.7%)
Antenatal steroids given (N, %)	3268 (91.5%)	231 (90.9%)	149 (92.0%)
Maternity Unit characteristics			
Total number of maternity units	150	18	12
With no neonatal service	3	3	2
With Special Care Baby Unit / Local Neonatal Unit	106	6	7
With Neonatal Intensive Care Unit	41	9	3
Births per level of unit (N, %)			
With no neonatal service	6 (0.2%)	6 (2.4%)	11 (6.8%)
With Special Care Baby Unit / Local Neonatal Unit	1329 (37.2%)	36 (14.2%)	49 (30.3%)
With Neonatal Intensive Care Unit	2238 (62.6%)	212 (83.5%)	102 (63.0%)
Average number of eligible births per hospital per month (mean, sd)	2.8 (2.1)	2.3 (1.3)	2.1 (1.6)

524 0. Baseline period is means/proportions across Jan-Dec 2017, the year before the NPP was rolled-out in England.

525 1. Babies up to 30 weeks' gestational age. Descriptive data is on all babies including multiples. Analysis is restricted to singletons and first-born of multiples.

526 2. Unique mother IDs

527 3. English, Scottish and Welsh Indices of Multiple Deprivation are calculated differently and are not comparable between nations.

528

529

530 **Table 2: Change in MgSO₄ uptake in England from before to after the NPP⁰**

	Step-change in MgSO ₄ uptake after intervention (percentage points) ¹	95% CI	p-value	Change in slope post-intervention compared to pre-intervention	95% CI	p-value	Overall slope post-intervention	95% CI	p-value
Unadjusted ²	11.8	10.0 to 13.6	<0.001	-	-	-			
Fully adjusted ³	5.8	2.7 to 8.9	<0.001	-0.87	-1.18 to -0.57	<0.001	0.02	-0.06 to 0.10	0.622
Cumulative increase per-year across the follow-up period²									
Year 1	3.1	-1.3 to 7.4	0.167	-0.76	-1.48 to -0.05	0.037	0.19	-0.31 to 0.69	0.450
Year 1-2	3.5	-0.2 to 7.3	0.067	-0.57	-0.91 to -0.23	<0.001	0.25	0.09 to 0.41	0.002
Year 1-3	5.6	2.1 to 9.1	0.002	-0.86	-1.25 to -0.48	<0.001	0.05	-0.05 to 0.16	0.302
Year 1-4	5.8	2.7 to 8.9	<0.001	-0.87	-1.17 to -0.57	<0.001	0.02	-0.06 to 0.10	0.622
Secondary, sensitivity and sub-group analyses²									
Analysis at maternity-unit level ⁴	5.8	2.8 to 8.8	<0.001	-0.83	-1.47 to -0.18	0.012	0.003	-0.05 to 0.06	0.923
Analysis at individual-level ⁴	5.9	2.5 to 9.3	0.001	-0.76	-1.17 to -0.34	<0.001	0.02	-0.03 to 0.07	0.449
Excluding implementation start window (2 months each side of start)	6.6	2.9 to 10.3	<0.001	-0.86	-1.17 to -0.54	<0.001	-0.01	-0.09 to 0.07	0.820
Excluding final 2 months (?data quality)	5.8	2.6 to 8.9	<0.001	-0.82	-1.14 to -0.50	<0.001	0.04	-0.04 to 0.12	0.346
Comparing 4 years pre with 4 years post	6.0	3.7 to 8.4	<0.001	-0.74	-0.82 to -0.65	<0.001	0.01	-0.07 to 0.08	0.895
PReCePT cRCT units only (n=40)	8.6	2.4 to 14.9	0.007	-0.79	-1.37 to -0.20	<0.001	0.04	-0.09 to 0.16	0.563
Including babies up to 34 weeks gestation	8.7	6.4 to 11.0	<0.001	-0.69	-0.90 to -0.48	<0.001	0.046	-0.02 to 0.11	0.157

531 ⁰ All data on singletons and first born of multiples <30 weeks' gestation and admitted to an NHS Neonatal unit

532 ¹ Percentage point difference in uptake between mean across the 12m pre-NPP, and mean across the four years post-NPP² Crude regression of uptake post-implementation compared with pre-implementation.

533 ³ Fully adjusted model: includes interaction between pre-post period and study month to capture change in slope as well as step-change. Adjusted for covariates as monthly aggregates: mean maternal age,
 534 proportion who identified as of white British ethnicity, mean IMD decile, proportion of multiple births, proportion with pregnancy hypertension, reported smokers, type of birth (c-section versus vaginal delivery),
 535 birthweight adjusted for gestational age as a z-score. Model weighted on unit size.

536 ⁴ Additionally adjusted for level of birth unit, and regional clustering by AHSN.

537

538 **Table 3. Probabilistic Cost-Effectiveness Results of the NPP from Interrupted Time Series Analysis (<30 weeks' gestation)**

	Main analysis (linear distribution counterfactual)	Sensitivity analysis (beta distribution counterfactual)
Period of benefit, months	7	10
Number of pre-term babies (≤ 3 weeks), N	2136	3129
Change in proportion of pre-term babies treated with MgSO ₄ , Δb_i , %	3.0% (1.5%; 4.5%)	2.9% (2.3%; 3.6%)
Net Increment of pre-term babies treated with MgSO ₄ , Δpat	64 (32; 97)	92 (72; 112)
Net cost of implementation, ΔC_i , £	936747	936747
Implementation cos-effectiveness, $\Delta C_i / \Delta Pat$, £ per additional patient treated	14576 (29284; 9669)	10219 (13040; 8386)
Lifetime health effect of MgSO ₄ treatment per patient, Δbt , QALY	0.24 (0.16; 0.33)	0.24 (0.16; 0.33)
Lifetime costs of MgSO ₄ treatment per patient, Δct , £	-19064 (-13310; -25648)	-19064 (-13310; -25648)
Net Monetary Benefit of the Policy, NMB_p , £ ¹	596538 (-221748; 1541786)	1251511 (558115; 2071244)
Probability of being cost-effective, %	89%	100%

539 ¹ At a willingness-to-pay threshold of £20,000 per QALY gained

540

541

542

543

544

545 **Figure 1: MgSO4 uptake in England, Scotland and Wales, 2014 to 2022**

546 **Figure 2: Predicted MgSO4 uptake, Counterfactual and Area-Between-Curves from Interrupted Time Series analyses**

547

Figure 1. MgSO₄ uptake in England, Scotland and Wales, 2014 to 2022




Figure 2. Predicted MgSO₄ uptake, Counterfactual and Area-Between-Curves from Interrupted Time Series analyses

